J. Stille

发表

Population Pharmacokinetic and Pharmacodynamic Modeling of LY2510924 in Patients With Advanced Cancer

E. Ludwig, J. Fiedler-Kelly, J. Hing, 2017, CPT: pharmacometrics & systems pharmacology.

537P A phase I/II study of oral chk1 inhibitor LY2880070 in combination with low-dose gemcitabine in patients with advanced or metastatic ovarian cancer

A. Oza, D. Provencher, A. Shields, 2022, Annals of Oncology.

SAT0502 A randomized, placebo-controlled, proof-of-concept efficacy study of a microsomal prostaglandin e synthase-1 (MPGES1) inhibitor and a prostaglandin E receptor (EP4) antagonist in the treatment of canine osteoarthritis pain

M. Warner, S. Malcolm, M. Fisher, 2017 .